CA2708173A1 — Targeting lipids
Assigned to Alnylam Pharmaceuticals Inc · Expires 2009-07-02 · 17y expired
What this patent protects
The present invention provides targeting lipids of structure (Cl) L100 -linker - L101 where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or - CH2CH2(OCH2CH2)p O(CH2)q CH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositio…
USPTO Abstract
The present invention provides targeting lipids of structure (Cl) L100 -linker - L101 where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or - CH2CH2(OCH2CH2)p O(CH2)q CH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic aicd to cellsin vivo.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.